But Same Medical Study Finds That DPP-4 Inhibitors Do Not Increase Risk Of Inflammatory Bowel Disease (IBD)
Back in March 2018 we wrote this report, "Januvia, Onglyza, And Certain Other Diabetes Drugs Linked To Inflammatory Bowel Disease (IBD)", which was about a study published by The BMJ medical journal about the use of dipeptidyl peptidase-4 (DPP-4) inhibitors for treatment of type 2 diabetes being associated with increased risk for IBD.
Now, about a year later, the medical journal Annals of Pharmacotherapy has published an article, "Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis", which concludes that DPP-4 inhibitors do not appear to increase the risk of developing IBD -- but goes on to point out that these drugs, such as Januvia and Onglyza, increase the risk of Crohn's disease (CD).
The following diabetes medicines are in the DPP-4 inhibitor class of drugs:
Janumet (sitagliptin / metformin HCl)
Janumet XR (sitagliptin / metformin HCl)
Jentadueto (linagliptin / metformin HCl)
Glyxambi (empagliflozin / linagliptin)
Kombiglyze XR (saxagliptin and metformin)
Qtern (dapagliflozin and saxagliptin)
Kazano (alogliptin and metformin)
Oseni (alogliptin and pioglitazone)
Strictly Confidential, No Obligation.
From the Abstract for this new Annals of Pharmacotherapy article, published on January 30, 2019, we get the following:
- Objective: This meta-analysis aims to elucidate the risk for [inflammatory bowel disease (IBD)] with DPP-4 inhibitor therapy.
- Results: A total of 16 individual studies evaluating a total of 198 404 patients were included for analysis. Studies ranged from 52 weeks through 5 years. In the primary random-effects analysis, DPP-4 inhibitor exposure resulted in a nonsignificant increase in the risk of [inflammatory bowel disease (IBD)] (RR = 1.52; 95% CI = 0.72 to 3.24; I2 = 54.2%).... DPP-4 inhibitor use significantly increased the risk of [Crohn's disease (CD)] (RR = 2.47; 95% CI = 1.36 to 4.48)....
- Conclusion and Relevance: Based on a conservative random-effects analysis, DPP-4 inhibitors do not appear to increase the risk of developing inflammatory bowel disease. However, long-term postmarketing surveillance is warranted.
In summary, this recent study found that the DPP-4 inhibitor class of drugs is not associated with IBD; however, DPP-4 inhibitor diabetes drugs, such as Januvia and Onglyza, increase the risk of Crohn's disease (CD).
Be assured that we will continue to monitor the safety profile of these DPP-4 diabetes drugs.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects (All website content by attorney Tom Lamb)
Drug Injury Case Evaluation - Free. Confidential. No Obligation. (Case review done by attorney Tom Lamb)